
    
      This is a blinded Phase II study of ERC1671 in combination with bevacizumab in patients with
      relapsed, bevacizumab naive glioblastoma. The patients who will be randomized (in a 1:1
      ratio) to receive either ERC 1671 in combination with GM-CSF and cyclophosphamide or a
      placebo control, in combination with bevacizumab. The study will be double blinded.

      ERC1671/GM-CSF will be intradermally administered, while cyclophosphamide is orally
      administered. GM-CSF dose is 500mcg fixed dose and cyclophosphamide dose is 50 mg/day.
      Bevacizumab or approved bevacizumab biosimilars are administered as standard of care at 10
      mg/kg every 2 weeks.

      The treatment cycles will be 28 days long.
    
  